Neurocrine Biosciences, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how the company is performing and whether it's growing or shrinking.
Major acquisitions change company size and add new products or services that can affect future profits.
Plan changes affect how employees are paid and can impact company costs and employee loyalty.
Board elections determine who oversees the company and makes major decisions on behalf of shareholders.
Quarterly earnings show how the company is performing and whether it's growing or shrinking.
Stocky reads Neurocrine Biosciences, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Neurocrine Biosciences, Inc.'s most recent tracked filing was a 10-Q on 31 Jul 2026: Neurocrine reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.